Sawtooth Solutions LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 15.5% during the 3rd quarter, Holdings Channel reports. The firm owned 1,371 shares of the medical technology company’s stock after purchasing an additional 184 shares during the quarter. Sawtooth Solutions LLC’s holdings in Stryker were worth $362,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in SYK. Gateway Advisory LLC lifted its holdings in shares of Stryker by 4.5% in the third quarter. Gateway Advisory LLC now owns 867 shares of the medical technology company’s stock valued at $229,000 after purchasing an additional 37 shares in the last quarter. Private Capital Group LLC increased its position in shares of Stryker by 11.0% during the third quarter. Private Capital Group LLC now owns 395 shares of the medical technology company’s stock valued at $104,000 after acquiring an additional 39 shares during the last quarter. Harrington Investments INC increased its position in shares of Stryker by 0.4% during the third quarter. Harrington Investments INC now owns 8,787 shares of the medical technology company’s stock valued at $2,317,000 after acquiring an additional 39 shares during the last quarter. 9258 Wealth Management LLC increased its position in shares of Stryker by 2.4% during the second quarter. 9258 Wealth Management LLC now owns 1,730 shares of the medical technology company’s stock valued at $449,000 after acquiring an additional 40 shares during the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in shares of Stryker by 1.5% during the second quarter. Brown Brothers Harriman & Co. now owns 3,056 shares of the medical technology company’s stock valued at $794,000 after acquiring an additional 44 shares during the last quarter. Institutional investors and hedge funds own 73.28% of the company’s stock.
Shares of NYSE SYK opened at $266.71 on Friday. The stock has a market cap of $100.58 billion, a PE ratio of 53.66, a price-to-earnings-growth ratio of 2.90 and a beta of 1.01. Stryker Co. has a fifty-two week low of $220.90 and a fifty-two week high of $281.16. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.35 and a current ratio of 2.13. The stock has a fifty day moving average of $261.02 and a 200-day moving average of $265.15.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 31st. Investors of record on Friday, December 31st will be paid a dividend of $0.695 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Thursday, December 30th. This represents a $2.78 annualized dividend and a yield of 1.04%. Stryker’s dividend payout ratio (DPR) is currently 55.94%.
In other Stryker news, Director Srikant M. Datar sold 1,000 shares of Stryker stock in a transaction dated Thursday, November 11th. The stock was sold at an average price of $263.12, for a total transaction of $263,120.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Glenn S. Boehnlein sold 2,778 shares of Stryker stock in a transaction dated Friday, December 10th. The stock was sold at an average price of $259.79, for a total value of $721,696.62. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.
A number of analysts recently commented on the company. Morgan Stanley downgraded Stryker from an “overweight” rating to an “equal weight” rating and set a $305.00 price target for the company. in a research report on Friday, January 7th. They noted that the move was a valuation call. Piper Sandler raised Stryker from a “neutral” rating to an “overweight” rating and increased their price target for the company from $250.00 to $315.00 in a research report on Tuesday, January 4th. SVB Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Friday, October 22nd. Loop Capital assumed coverage on Stryker in a research report on Monday, December 6th. They issued a “buy” rating and a $305.00 target price for the company. Finally, Royal Bank of Canada assumed coverage on Stryker in a research report on Thursday, December 9th. They issued a “sector perform” rating and a $278.00 target price for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $293.74.
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg, and Neurotechnology & Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.
Read More: What is FinTech?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.